Lubiprostone for the Treatment of Chronic Idiopathic Constipation

Summary

The purpose of this study is to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.

Timeline

Start

2016-03-02

Primary completion

2017-01-11

Completion

2017-01-11

Outcome

Met primary endpoint

registry Placebo vs Lubiprostone 24 μg; p = 0.003; Median Values of CI 1.0 (95% CI 0.1 to 1.0); Van Elteren Test NCT02651155 ↗

Drugs

Indications